Figure 2.

A) Incidence of any acute kidney injury (AKI) based on Common Terminology Criteria for Adverse Events (CTCAE) vs Kidney Disease Improving Global Outcomes (KDIGO) criteria. B) Incidence of any AKI based on CTCAE among olaparib-treated and niraparib-treated patients. Based on CTCAE criteria (version 5.0), 70 patients had any AKI, of whom 51 (72.8%) had grade 1, 16 (22.9%) had grade 2, and 4 (4.3%) had grade 3. Based on KDIGO criteria, 60 patients had AKI, of whom 55 (91.7%) had stage I, 3 (5.0%) had stage II, and 2 (3.3%) had stage III AKI.